Continuous manufacturing in solid dose, more accurately named “continuous tablet manufacturing”, is getting increasing attention in solid dose pharma development. Due to the necessity of profound process stability, this manufacturing mode is very much supported by regulatory authorities. QbD is a must in this case and this reflects the choice of excipients as well. Performance criteria like flow, bulk density, and compressibility play an important role. Moreover, this technology shows some specific requirements which are not achieved by some excipients frequently used before.
In this webinar you will learn:
Strategic Marketing Manager
Leo Ohrem is a strategic marketing manager and has been with Merck for more than 23 years. With an engineering background and degrees from the University of Aachen, Germany, and Cornell University, NY, USA, Leo has expertise in solid dose excipients and formulation technologies. Leo has experience in handling customer projects, production process development, regulatory support, and audits, as well as complaint management. Furthermore, he has been leading a development group and pilot plant unit for more than 5 years.
Pharma and biopharma manufacturing
Session 1:presented October 15, 2020
To continue reading please sign in or create an account.Don't Have An Account?